H. A. TUFAN Et Al. , "Intravitreal Bevacizumab Treatment for Chronic Central Serous Chorioretinopathy Presumably Associated with Trigger Point Steroid Injection," Retina-Vitreus.2013;21(3):219-222. , 2013
TUFAN, H. A. Et Al. 2013. Intravitreal Bevacizumab Treatment for Chronic Central Serous Chorioretinopathy Presumably Associated with Trigger Point Steroid Injection. Retina-Vitreus.2013;21(3):219-222. .
TUFAN, H. A., GENCER, B., TAŞKIRAN ÇÖMEZ, A., & ÖZDEK, Ş., (2013). Intravitreal Bevacizumab Treatment for Chronic Central Serous Chorioretinopathy Presumably Associated with Trigger Point Steroid Injection. Retina-Vitreus.2013;21(3):219-222. .
TUFAN, HASAN Et Al. "Intravitreal Bevacizumab Treatment for Chronic Central Serous Chorioretinopathy Presumably Associated with Trigger Point Steroid Injection," Retina-Vitreus.2013;21(3):219-222. , 2013
TUFAN, HASAN A. Et Al. "Intravitreal Bevacizumab Treatment for Chronic Central Serous Chorioretinopathy Presumably Associated with Trigger Point Steroid Injection." Retina-Vitreus.2013;21(3):219-222. , 2013
TUFAN, H. A. Et Al. (2013) . "Intravitreal Bevacizumab Treatment for Chronic Central Serous Chorioretinopathy Presumably Associated with Trigger Point Steroid Injection." Retina-Vitreus.2013;21(3):219-222. .
@article{article, author={HASAN ALİ TUFAN Et Al. }, title={Intravitreal Bevacizumab Treatment for Chronic Central Serous Chorioretinopathy Presumably Associated with Trigger Point Steroid Injection}, journal={Retina-Vitreus.2013;21(3):219-222.}, year=2013}